• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Roth David converted options into 18,875 shares and covered exercise/tax liability with 6,776 shares (SEC Form 4)

    11/4/24 5:01:40 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYRS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Roth David

    (Last) (First) (Middle)
    C/O SYROS PHARMACEUTICALS, INC.
    35 CAMBRIDGEPARK DRIVE

    (Street)
    CAMBRIDGE MA 02140

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Syros Pharmaceuticals, Inc. [ SYRS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    10/31/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/31/2024 M 18,875(1) A (1) 18,875 D
    Common Stock 10/31/2024 F(2) 6,776 D $2.09 12,099 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (3) 10/31/2024 M 18,875 (4) (4) Common Stock 18,875 $0 0 D
    Explanation of Responses:
    1. Represents shares of common stock received upon vesting of a restricted stock unit award.
    2. Represents shares used to cover tax withholding on a restricted stock unit release.
    3. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
    4. Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
    /s/ Todd Rosenthal, as attorney-in-fact 11/04/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SYRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYRS

    DatePrice TargetRatingAnalyst
    9/23/2021$20.00 → $23.00Buy
    Roth Capital
    More analyst ratings

    $SYRS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Syros Pharmaceuticals Inc.

      15-12G - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/20/25 5:01:35 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Syros Pharmaceuticals Inc.

      144 - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      3/14/25 4:43:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:11 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Financials

    Live finance-specific insights

    See more
    • Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

      KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA, (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant po

      4/15/25 1:20:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

      -- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. "It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. We expect to announ

      10/31/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 07454. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 da

      10/24/24 7:08:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

      KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA, (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant po

      4/15/25 1:20:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

      Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market ("Nasdaq") and the deregistration of its common stock in order to terminate and suspend the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified Nasdaq of its intention to voluntarily delist its shares of common stock from the Nasdaq Global Select Market. The Company intends to file a Form 25 with the Securities and Exchange Commission ("SEC") to effect the delisting

      2/28/25 4:05:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

      -- SELECT-MDS-1 Did Not Meet its Primary Endpoint -- -- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Syros' proprietary oral, selective, retinoic acid receptor alpha (RARα) agonist. In the first 190

      11/12/24 4:30:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Simonian Nancy A sold $10,016 worth of shares (37,070 units at $0.27), decreasing direct ownership by 90% to 4,000 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      12/4/24 5:00:05 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Simonian Nancy A sold $35,739 worth of shares (134,713 units at $0.27), decreasing direct ownership by 77% to 41,070 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/27/24 5:00:04 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Stephens Kristin sold $7,949 worth of shares (36,133 units at $0.22), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:16 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Leadership Updates

    Live Leadership Updates

    See more

    $SYRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SYRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SYRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

      -- Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors -- -- Planned workforce reduction of approximately 35% sharpens focus of organization on late-stage development of tamibarotene in MDS and AML and ongoing pre-launch activities -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the frontline treatment of higher-risk myelodysplastic

      10/2/23 8:45:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

      Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros. "We are pleased to welcome Jason to Syros, who brings an exceptional depth of financial, strategic, and leadership experience in the life sciences space," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Jason has a proven track record as a strategic advisor to biotechnology and pharmaceutical companies across all stages of development. He joins Syros at a pivotal time, as we advan

      10/12/21 8:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on Syros Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Syros Pharmaceuticals with a rating of Buy and set a new price target of $23.00 from $20.00 previously

      9/23/21 9:11:45 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on Syros Pharmaceuticals with a new price target

      Alliance Global Partners reiterated coverage of Syros Pharmaceuticals with a rating of and set a new price target of $14.00 from $18.00 previously

      3/5/21 4:01:58 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Haas Jason bought $161,240 worth of shares (100,000 units at $1.61), increasing direct ownership by 407% to 124,552 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      9/12/24 5:00:03 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Chee Conley bought $160,680 worth of shares (100,000 units at $1.61), increasing direct ownership by 444% to 122,504 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      9/12/24 5:00:03 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akkaraju Srinivas bought $3,999,998 worth of shares (904,977 units at $4.42) (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      12/26/23 5:24:30 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:28:08 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:24:48 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:05:24 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care